Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 548ag-1 (miR-548ag-1) is a short, non-coding RNA molecule in the microRNA family that functions mainly by post-transcriptional repression of target gene expression[3][1]. It acts as an oncogene in the development of obesity-related endometrial cancer by downregulating the tumor suppressor gene MOB1B, leading to deactivation of the Hippo pathway and enhanced tumor cell proliferation, invasion, and migration while inhibiting apoptosis[1][3]. Elevated levels of miR-548ag-1 are associated with poorer prognosis in endometrial cancer. It may serve as a biomarker for diagnosis and prognosis in specific cancer contexts, but is not currently considered a direct therapeutic receptor or enzyme target[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 548ag-1 (miR-548ag-1).